0-7-21 hypofractionated palliative radiotherapy: an effective treatment for advanced XXXX .

@entity1 @entity135 @entity137 @entity5 @entity1349
OBJECTIVE: We report our experience in providing palliative radiotherapy (RT) to @entity1 with @entity135 ( @entity135 ). Our hypofractionated regimen, "0-7-21", treats @entity1 with 24   Gy in three fractions. METHODS: @entity1 , disease and response data were retrieved for candidates of 0-7-21 from 2005 to 2012. Primary end points included symptom and @entity5 size responses to RT based on response evaluation criteria in solid @entity5 (RECIST) guidelines. Secondary end points included progression-free survival (PFS) within the irradiated field, @entity1349 ( @entity1349 ) and symptomatic PFS (SPFS), calculated using Kaplan-Meier method and adverse events. Cox proportional hazards regression and logistic regression were used to investigate for prognostic factors. RESULTS: A total of 110 @entity1 were included. Among the @entity1 , 40% and 31% had complete response for symptoms and @entity5 size, respectively; 42% and 50% had partial response for symptoms and @entity5 size, respectively; and 15% had stability of symptoms and @entity5 size. Median 6-month @entity1349 was 51%, and PFS within the irradiated field was 39%. Planning target volume was predictive of @entity1349 (p   <   0.001), PFS (p   <   0.001) and SPFS (p   <   0.005), while higher TNM stage was associated with poorer @entity5 response (p   =   0.02). CONCLUSION: 0-7-21 is an effective and well-tolerated palliative RT regimen for @entity1 with HNC. There was excellent symptom and local control with acceptable @entity137 profile in these @entity1 . ADVANCES IN KNOWLEDGE: This is the first study to describe the outcomes of 0-7-21 in treating advanced @entity135 . The positive results suggest that 0-7-21 provides excellent palliation with minimal @entity137 , with significantly less on-treatment time than current published palliative RT regimen.
